Does Forteo Build Bone Mass?
Forteo (teriparatide) increases bone mass in patients with osteoporosis at high risk of fracture. It is a synthetic form of parathyroid hormone that stimulates osteoblasts to form new bone, leading to measurable gains in bone mineral density (BMD). Clinical trials show it raises lumbar spine BMD by 9-13% and femoral neck BMD by 3-5% after 18-24 months of daily subcutaneous injections.[1][2]
How Does Forteo Work to Build Bone?
Forteo mimics the first 34 amino acids of human parathyroid hormone, activating bone-forming cells rather than resorption like bisphosphonates. Given intermittently (once daily), it promotes anabolic effects: new bone formation outpaces resorption, net increasing trabecular and cortical bone mass. This differs from antiresorptive drugs that mainly preserve existing bone.[1][3]
Evidence from Key Clinical Trials
In the Fracture Prevention Trial, postmenopausal women on Forteo gained 12.2% lumbar spine BMD vs. 0.3% on placebo after 21 months, with similar gains in men and glucocorticoid-induced osteoporosis patients. Reductions in vertebral fractures (65%) and nonvertebral fractures (53%) correlated with BMD increases.[2][4] Long-term extensions confirm sustained gains up to 2 years, though use is capped at 2 years lifetime due to osteosarcoma risk in animal studies.[1]
How Much Bone Mass Gain Can Patients Expect?
Gains vary by site and population:
- Lumbar spine: 8-13% at 18-24 months.
- Total hip: 2-4%.
- Femoral neck: 3-5%.
Younger patients or those with lower baseline BMD see higher increases. Post-treatment, BMD declines slowly without follow-on therapy like bisphosphonates.[1][2]
What Happens After Stopping Forteo?
Bone mass peaks after 18-24 months, then declines 3-6% at spine over 1 year if untreated. Sequential therapy with antiresorptives (e.g., alendronate) preserves most gains, maintaining fracture risk reduction.[4][5]
Comparison to Other Osteoporosis Treatments
| Treatment | Mechanism | Spine BMD Gain (18-24 mo) | Fracture Reduction |
|-----------|-----------|---------------------------|-------------------|
| Forteo | Anabolic | 9-13% | Vertebral: 65% |
| Prolia (denosumab) | Antiresorptive | 7-9% | Vertebral: 68% |
| Fosamax (alendronate) | Antiresorptive | 5-7% | Vertebral: 47% |
| Evenity (romosozumab) | Dual (anabolic then antiresorptive) | 12-15% | Vertebral: 73% |
Forteo excels in rapid, high-magnitude gains for severe cases but requires injections.[3][6]
Common Patient Concerns: Side Effects and Risks
Forteo builds bone effectively but carries a black box warning for osteosarcoma risk (rodent data; rare in humans). Other effects include leg cramps (3%), dizziness (3%), and hypercalcemia (1-2%). Not for use in Paget's disease, bone metastases, or prior radiation. Monitor calcium levels.[1]
Who Qualifies and What's the Cost?
Approved for postmenopausal women, men with osteoporosis, or glucocorticoid users at high fracture risk. Daily 20 mcg injection pen; 2-year max. List price ~$2,500/month (U.S., varies by insurance).[1][7] Generics unavailable; patent expires 2025 in U.S.—check DrugPatentWatch.com for updates.[8]
Sources
[1]: Forteo Prescribing Information (FDA)
[2]: NEJM: Teriparatide Fracture Prevention Trial (2001)
[3]: Endocrine Reviews: PTH Anabolic Effects (2006)
[4]: J Bone Miner Res: Post-Forteo Effects (2005)
[5]: Lancet: Sequential Therapy (2007)
[6]: Prolia/Evenity Labels (FDA)
[7]: GoodRx Pricing Data (2023)
[8]: DrugPatentWatch: Forteo Patents